HTG said this week that Lee Hartwell and Timothy Yeatman have joined the company's scientific advisory board.
Hartwell is president and director of the Fred Hutchinson Cancer Research Center. Yeatman is executive vice president, co-founder, and chief scientific officer of M2Gen.
HTG, based in Tucson, Ariz., provides quantitative nuclease protection assay, or qNPA, technology, which is well-suited for identifying and validating biomarkers from formalin-fixed, paraffin-embedded samples, HTG said.
Expression Analysis has named Patrick Hurban as vice president of research and development and Louise Grant as director of operations.
Hurban joins Expression Analysis from Beckman Coulter Genomics, where he was the global business line leader for gene expression. He has also served as executive director of scientific affairs and director of technology development at Cogenics, a predecessor of Beckman Coulter Genomics. He has also worked for Icoria and Paradigm Genetics.
Hurban holds a PhD from the University of Utah School of Medicine and completed his postdoc at Stanford University School of Medicine.
Grant most recently served as microbiology program director at Biomérieux. She has also worked in research and development, technical support, and product management for Becton Dickinson; and conducted clinical laboratory work and research at the Johns Hopkins Medical Institutions.
Siemens Healthcare Diagnostics said recently that Donal Quinn has been appointed to AdvaMed Dx's board of directors.
Quinn joins an 18-member board comprising executives from leading diagnostic companies worldwide.
AdvaMed Dx, a division of AdvaMed, was recently formed to advance the public policy priorities of AdvaMed's diagnostic member companies and provide a dedicated vehicle that represents the interests of the in vitro diagnostics industry.